11C- and 18F-Choline PET/MR Imaging for Prostate Cancer

Inclusion Criteria:

* Age: Patients must be \>=18 years of age
* Diagnosis: Patients must have a diagnosis of prostate cancer by histologic verification and a hypoechoic lesion seen on ultrasound.
* Disease Status: Unfavorable intermediate to high-risk prostate cancer, per the Cancer of the Prostate Risk Assessment Score (CAPRA) (CAPRA 5-10)
* Karnofsky Performance Status \>=70
* Metastatic workup: Whole Body Sodium Fluoride (NaF) PET/CT or 99mTc Bone Scan
* Planned to undergo radical prostatectomy and extended pelvic lymph node dissection
* Adequate bone marrow and organ function defined as follows:
* Adequate bone marrow function:
* Leukocytes \>= 3,000/microliter (mcL)
* Absolute Neutrophil Count \>= 1,500/mcL
* Platelets \>= 100,000/mcL
* Adequate hepatic function:
* Total bilirubin - within normal institutional limits
* Aspartate aminotransferase (AST)/ serum glutamic-oxaloacetic transaminase (SGOT) \<= 2.5 X institutional upper limit of normal
* Alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) \<= 2.5 X institutional upper limit of normal
* Adequate renal function:
* Creatinine - within normal institutional limits OR
* Creatinine clearance \>= 60 mL/min/ 1.73m2 for patients with creatinine levels above institutional normal
* Ability to understand a written informed consent document, and the willingness to sign it

Exclusion Criteria:

* Participation would significantly delay the scheduled standard of care therapy
* Karnofsky performance status of \< 60
* Inadequate venous access
* Administered a radioisotope within 5 physical half lives prior to study enrollment
* Have a medical condition or other circumstances which, in the opinion of the investigator would significantly decrease the chances of obtaining reliable data, achieving the study objectives, or completing the study.